rheumatology oncology
Cytokine Release Syndrome (CRS) Grading
ASTCT 2019 consensus grading of cytokine release syndrome (CRS) following CAR-T cell therapy, bispecific antibodies, or other immunotherapy. Grade 1–4. Guides management with tocilizumab and corticosteroids.
References
- Lee DW et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625–638.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Tocilizumab (ICU — Cytokine Storm / COVID-19) · IL-6 Receptor Inhibitor
- Nebivolol · Cardioselective β1-blocker (with NO release)
- Grass pollen extracts · Allergen immunotherapy
- House dust mite extracts · Allergen immunotherapy
- Hydrocortisone (Oral Replacement) · Glucocorticoid Replacement
- Aciclovir 800mg Tablets (Ramsay Hunt Syndrome / Herpes Zoster Oticus) · Antiviral — nucleoside analogue (herpes zoster treatment)
Pathways
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.